Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

Molecular Cancer Therapeutics

Volumn 8, Issue 10, 2009, Pages 2872-2881

  Daenen, Laura G ^a,b   Shaked, Yuval ^c   Man, Shan ^a   Xu, Ping ^a   Voest, Emile E ^b   Hoffman, Robert M ^d,e   Chaplin, David J ^f   Kerbel, Robert S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d ANTICANCER INC   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f Oxigene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A1 PHOSPHATE; CYCLOPHOSPHAMIDE; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIL 231 LM2 4; CELL STRAIN MEWO; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MELANOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REPEATED DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW CELLS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DIPHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICROVESSELS; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350231754     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0583     Document Type: Article

References (50)

1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab,an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-2049
3. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134 (Pubitemid 46089673)
5. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol ASCO Annual Meeting Proceedings 2007;25;LBA1.
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-435
7. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:1375-1380 (Pubitemid 46467170)
8. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-11539
9. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004;60:1233-1240 (Pubitemid 39440810)
10. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-2031
11. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-1787 (Pubitemid 44454154)
12. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14: 263-273
13. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26 suppl:ASCO:Abstract 3550.
14. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047 (Pubitemid 30217688)
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436
16. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63:4342-4346 (Pubitemid 36951001)
17. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;16:1243-1252
18. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-4905
19. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
20. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-3391
21. Yang M, Reynoso J, Jiang P, Li L, Moossa AR, Hoffman RM. Transgenic nude mouse with ubiquitous green fluorescent protein expression as a host for human tumors. Cancer Res 2004;64:8651-8656 (Pubitemid 39552079)
22. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-2735 (Pubitemid 34525751)
23. Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anti-cancer Res 2002;22:1453-1458
24. Monestiroli S, Mancuso P, Burlini A,e t al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4344
25. Philpott NJ, Turner AJ, Scopes J, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996;87:2244-2251 (Pubitemid 26086863)
26. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, Van Der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000;48:571-582
27. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-3061 (Pubitemid 41565900)
28. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-111 (Pubitemid 40126386)
29. Klement G, Baruchel S, Rak J,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24. (Pubitemid 30217701)
30. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886 (Pubitemid 30207647)
31. Pietras K, Hanahan D. A multitargeted,metronom ic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic,producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952
32. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63:8408-8413 (Pubitemid 37549496)
33. Francia G, Emmenegger U, Lee CR, et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther 2008;7:3452-3459
34. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009;16:7-15.
35. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623-3628 (Pubitemid 46630536)
36. Buckstein R, Kerbel RS, Shaked Y,et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-5198
37. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17:232-238 (Pubitemid 43160111)
38. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225. (Pubitemid 44501753)
39. Shaked Y, Tang T, Woloszynek J, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 2009;69:7524-7528
40. Kolata G, Pollack A. Costly cancer drug offers hope, but also a dilemma. The New York Times 2008;Jul 6;1.
41. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24: 1491-1498
42. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100. (Pubitemid 38114167)
43. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
44. Roodhart JM, Langenberg MH, Daenen LG, Voest EE. Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta 2009;1796: 41-49
45. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-835
46. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201 (Pubitemid 33063774)
47. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827 (Pubitemid 41753060)
48. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-198
49. Gille J, Heidenreich R, Pinter A, et al. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007; 120:1899-1908 (Pubitemid 46418365)
50. Francesconi A, Kotasek D, Burge M, Smith G, Lickliter J. Phase I evaluation of orally-administered CYT997,a novel cytotoxic vascular-disrupting agent,in patients with advanced cancer. J Clin Oncol ASCO Annual Meeting Proceedings 2009;27:3568.